中国医院用药评价与分析2025，Vol.25Issue(8)：928-931,937,5.DOI:10.14009/j.issn.1672-2124.2025.08.006
维立西呱辅助常规治疗用于冠心病慢性心力衰竭的疗效及对miR-155、miR-214的影响
Efficacy of Vericiguat in Assisting Conventional Treatment of Chronic Heart Failure and Its Effects on miR-155 and miR-214
摘要
Abstract
OBJECTIVE:To observe the efficacy of vericiguat in assisting conventional treatment of chronic heart failure(CHF)and its effects on miR-155 and miR-214.METHODS:A total of 142 patients with CHF admitted into the hospital from May 2022 to Dec.2023 were extracted to be divided into the control group(n=71)and observation group(n=71)according to the random number table method.The control group received conventional anti-heart failure treatment,while the observation group was given additional treatment with vericiguat.The treatment course was 3 months.The efficacy,cardiac function[left ventricular ejection fraction(LVEF),stroke volume(SV),and left ventricular end-diastolic diameter(LVEDD)],cardiovascular endothelial function[endothelin-1(ET-1),nitric oxide(NO),and soluble intercellular adhesion molecule-1(sICAM-1)],myocardial microcirculation,myocardial injury[Furin,neutrophil/lymphocyte ratio(NLR),and soluble tumor necrosis factor-like apoptosis weak inducer(sTWEAK)],miR-155,miR-214 before and after treatment,and the incidence of major adverse cardiac events(MACE)of two groups was compared.RESULTS:The total effective rate of observation group was 94.37%(67/71),higher than 76.06%(54/71)of the control group,with statistically significant difference(P<0.05).The expression of LVEF,SV,NO,and miR-214 in the observation group was higher than that in the control group after 1 and 3 months of treatment,the expression of LVEDD,ET-1,sICAM-1,ST-segment reduction frequency,total myocardial ischemic load,NLR,sTWEAK,Furin,and miR-155 was lower than that in the control group,and ST-segment reduction duration was shorter than that in the control group,with statistically significant difference(P<0.05).After 6-month follow-up,the incidence of MACE in observation group was 2.82%(2/71),and there was no statistically significant difference compared with the control group(9.86%,7/71)(P>0.05).CONCLUSIONS:The adjunctive treatment with vericiguat can improve the cardiac function and cardiovascular endothelial function in patients with CHF,promote myocardial microcirculation,reduce myocardial injury,regulate the expression of miR-155 and miR-214,with significant efficacy.关键词
冠心病/慢性心力衰竭/心血管内皮功能/维立西呱/主要不良心血管事件/心肌损伤Key words
Coronary heart disease/Chronic heart failure/Cardiovascular endothelial function/Vericiguat/Major adverse cardiac events/Myocardial injury分类
医药卫生引用本文复制引用
王璇,周巧瑞,马国锋,蒋冲..维立西呱辅助常规治疗用于冠心病慢性心力衰竭的疗效及对miR-155、miR-214的影响[J].中国医院用药评价与分析,2025,25(8):928-931,937,5.基金项目
陕西省重点研发计划项目(No.2022SF-1907) （No.2022SF-1907）
